Millions of Americans have turned to GLP-1 medications like Ozempic and Wegovy for weight loss, but a new study from the Department of Veterans Affairs reveals a concerning link between stopping these drugs and an increased risk of cardiovascular problems. Researchers found that individuals who discontinued GLP-1s experienced a 22% rise in adverse cardiovascular events, including stroke and heart failure. The findings underscore the importance of considering the long-term health implications of both initiating and stopping these increasingly popular medications.
The study, published in BMJ Medicine, analyzed data from over 333,000 veterans with type 2 diabetes over a period of up to three years. It simulated various treatment scenarios, from continuous apply to different durations of discontinuation and re-initiation, to assess the cardiovascular consequences. The research highlights that the cardiovascular benefits associated with GLP-1s aren’t simply a result of weight loss, but appear to be a direct effect of the medication itself.
Cardiovascular Protection Erodes with Discontinuation
Dr. Ziyad Al-Aly, director of the Clinical Epidemiology Center at the VA Saint Louis Health Care System and chief of Research and Development at the VA facility, led the study. He explained that the question of what happens to heart health when someone stops taking these weight loss drugs hadn’t received sufficient attention. “We examined a question that hasn’t received nearly enough attention: What are the cardiovascular consequences of stopping GLP-1 drugs?” he posted on LinkedIn.
The study demonstrated a progressive build-up of cardiovascular protection with continued GLP-1 use. After three years of consistent treatment, participants experienced an 18% reduction in major adverse cardiovascular events – encompassing heart attack, stroke, and death. However, this protection began to diminish rapidly upon discontinuation. Stopping the medication for just six months correlated with a 4% increase in cardiovascular risk, rising to 14% after one year and 22% after two years. Perhaps surprisingly, the research showed that restarting the medication didn’t fully restore the lost benefits. While it offered some improvement, it didn’t completely reverse the increased risk associated with stopping.
Beyond Weight Loss: Metabolic Reversal
The risks associated with stopping GLP-1s extend beyond weight regain. Researchers observed a spike in inflammation, blood pressure, cholesterol levels, and insulin resistance among patients who discontinued the medication. “Weight regain is visible. The metabolic reversal is not,” Al-Aly stated. “We think of this as a form of metabolic whiplash, and our data suggest it is detrimental to heart health.” This suggests that GLP-1s have a broader impact on metabolic health than previously understood, and that interrupting treatment can trigger a cascade of negative effects.
GLP-1 medications, initially approved by the Food and Drug Administration in 2005 with Exenatide for the treatment of type 2 diabetes, gained widespread popularity in 2021 with the release of Ozempic and Wegovy. According to Al-Aly, approximately 1 in 8 adults in the U.S. Has tried a GLP-1 medication. However, a significant proportion – between 36% and 81% – discontinue use within the first year, often due to achieving weight loss goals, concerns about side effects, or the high cost of the drugs.
Affordability and Access Remain Key Challenges
The study also highlights the significant barriers to long-term GLP-1 use, particularly affordability and insurance coverage. Within the VA healthcare system, copays are capped at $11 per month, but even with this reduced cost, over 25% of patients stopped using the medication, and another 25% temporarily halted treatment. Al-Aly noted that other factors contributing to discontinuation include side effects, patient perceptions of ineffectiveness, and ongoing drug shortages, which have strained supply chains due to high demand.
“The implications are clear: clinicians should treat persistence as a clinical outcome in its own right,” Al-Aly emphasized. “Health systems need to identify and support patients at risk of stopping. And policymakers need to address the barriers, financial and otherwise, that make continuous treatment unsustainable for many. The data demonstrate a clear dose-response: the more consistently people stay on, the greater the heart protection.”
The findings from this VA study add to a growing body of evidence suggesting that GLP-1 medications are not simply a quick fix for weight loss, but a potentially important tool for long-term cardiovascular health. However, maintaining that benefit requires ongoing treatment, a reality complicated by cost, access, and individual patient factors.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Researchers will continue to monitor the long-term effects of GLP-1 use and discontinuation, and further studies are planned to investigate the optimal duration of treatment and strategies to improve patient adherence. The FDA is expected to review updated safety data on GLP-1 medications in the coming months. Share your thoughts and experiences with GLP-1 medications in the comments below.
